Not Yet RecruitingNot Applicable

Inverted-Ω Anastomosis in Laparoscopic Duodenum-Preserving Pancreatic Head Resection or Laparoscopic Central Pancreatectomy

China20 participantsStarted 2025-07-20

Plain-language summary

The goal of this clinical trial is to learn if inverted-Ω anastomosis after pancreatic head resection or mid-pancreatectomy works in benign or low-grade malignant tumor. It will also learn about the safety and feasibility of inverted-Ω anastomosis. The main questions it aims to answer are: 1. Does inverted-Ω anastomosis operate safely? (operative time, blood loss, transfusion and conversion rate) 2. What is the incidence and severity of postoperative complications in inverted -Ω anastomosis? What advantages does it have over conventional anastomosis methods such as roux-en-y？

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18 to 75 years old, gender not limited;
✓. Patients diagnosed with benign or low-grade malignant tumors in the head or middle section of the pancreas by CT or MRI;
✓. ECOG score 0-1.

Exclusion criteria

✕. Those with severe heart, liver or kidney insufficiency, or those who are assessed as intolerant to surgery or anesthesia, or those with ASA grade \> 3;
✕. Patients with a history of or concurrent other malignant tumors, or other serious infections or infectious diseases, or those who are unable to complete the anastomosis surgery;
✕. Uncontrollable concomitant diseases, including but not limited to severe coronary artery disease, COPD or asthma, uncontrollable cerebrovascular diseases, symptomatic congestive failure, unstable angina pectoris, arrhythmia, or other diseases that the researchers consider ineligible for enrollment;
✕. Patients who have undergone other upper abdominal surgeries and digestive tract reconstruction procedures in the past;
✕

What they're measuring

Safety and assessment of the surgical process

Timeframe: During operation

Operative time

Timeframe: During operation

Intraoperative blood loss

Timeframe: During operation

Postoperative complications

Timeframe: From the date of surgery (Day 0) up to 90 days postoperatively

Trial details

NCT IDNCT07087392

SponsorWest China Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-07-20

Contact for this trial

Zhong Wu

+86 189 8060 6518 wuzhong0057@163.com

View on ClinicalTrials.gov More Pancreatic Cystic Neoplasms trials

Plain-language summary

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age 18 to 75 years old, gender not limited;
✓. Patients diagnosed with benign or low-grade malignant tumors in the head or middle section of the pancreas by CT or MRI;
✓. ECOG score 0-1.

Exclusion criteria

✕. Those with severe heart, liver or kidney insufficiency, or those who are assessed as intolerant to surgery or anesthesia, or those with ASA grade \> 3;
✕. Patients with a history of or concurrent other malignant tumors, or other serious infections or infectious diseases, or those who are unable to complete the anastomosis surgery;
✕. Uncontrollable concomitant diseases, including but not limited to severe coronary artery disease, COPD or asthma, uncontrollable cerebrovascular diseases, symptomatic congestive failure, unstable angina pectoris, arrhythmia, or other diseases that the researchers consider ineligible for enrollment;
✕. Patients who have undergone other upper abdominal surgeries and digestive tract reconstruction procedures in the past;
✕